No stem cell-derived aesthetic product has FDA approval as a drug. Exosomes, fibroblasts, and placental extracts used cosmetically typically fall outside drug regulation in most countries, marketed instead as cosmeceuticals or medical devices under lighter regulatory pathways. The EU has not approved any cell-derived aesthetic therapy as a medicinal product. This regulatory gap means quality assurance, purity, and efficacy labelling are inconsistent between suppliers.
Aesthetic treatments using stem cell derivatives—primarily exosomes and umbilical-cord fibroblasts—target skin ageing at the cellular level. Exosomes, tiny vesicles naturally released by stem cells, carry proteins and genetic material that may stimulate collagen production and improve skin texture. Umbilical-cord fibroblasts, harvested from donated umbilical tissue, are specialised cells responsible for maintaining skin structure in developing tissue. Placental extracts contain growth factors accumulated during foetal development. These cell-derived materials are investigated for reducing fine lines, improving elasticity, and enhancing overall skin luminosity. Unlike ablative procedures, they work by encouraging the skin's own repair mechanisms rather than removing tissue. Clinical interest has grown steadily, with 9 registered trials globally examining safety and efficacy across different age groups and skin types.
我是候选人吗？ → · Aesthetic & Anti-Ageing: full overview → · 美容与抗衰老成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估